{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071566","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.867059+00:00","generated_at":"2026-05-16T00:35:12.914187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B","bullets":["Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.","GAAP net loss Q4 $412.2M ($3.93/share) vs Q4 2024 net income $159.0M; full-year GAAP net loss $713.4M.","Ended 2025 with ~$1.0B cash; refinanced $291.4M of 2027 notes to 2030 notes, removing near-term debt.","Japan launch of ELEVIDYS by Chugai in Feb 2026; eligible for $40M milestone. Positive 3-year EMBARK results.","Approval to begin Phase 1 trial of SRP-1005 (siRNA) for Huntington’s disease; Phase 1/2 SRP-1003 for DM1 advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071566","json":"https://secwatch.observer/filing/0001193125-26-071566.json","markdown":"https://secwatch.observer/filing/0001193125-26-071566.md","text":"https://secwatch.observer/filing/0001193125-26-071566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/0001193125-26-071566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:35:12.914187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}